<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407703</url>
  </required_header>
  <id_info>
    <org_study_id>17-22790</org_study_id>
    <nct_id>NCT03407703</nct_id>
  </id_info>
  <brief_title>Hepatitis C (HCV) Cure and Kidney Health</brief_title>
  <official_title>HCV Cure and Kidney Health: A Prospective, Observational Cohort Study of HCV Genotype 1 and 4 Infected Adults With and Without HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Francisco Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>San Francisco Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn how 12 weeks of HCV treatment with elbasvir and
      grazoprevir (brand name Zepatier) impacts your kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective data collection of 25 Genotype 1 or 4 HCV-infected women from the San Francisco
      Women's Interagency HIV Study (WIHS) site and 25 Genotype 1 or 4 HCV-infected men from the
      San Francisco VA Medical Center who are initiated on Zepatier for 12 weeks (Total n=50). For
      women and men with HCV genotype 1a infection, only those without baseline NS5A resistance
      mutations will be included. Blood/urine samples will be collected before initiation of
      treatment, 4 weeks after treatment initiation, 12 weeks after treatment initiation (end of
      treatment), 24 weeks after treatment initiation to determine Sustained Virological Response
      (SVR), and at 48 weeks after treatment initiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate and injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glomerular filtration rate and injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glomerular filtration rate and injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by albuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tubule dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Î±1-microglobulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tubule dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>measured by beta2-microglobulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tubule injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Interleukin-18</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tubule injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Kidney injury molecule-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tubule injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Neutrophil gelatinase-associated lipocalcin (NGAL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tubule injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Clusterin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tubule injury</measure>
    <time_frame>1 year</time_frame>
    <description>measured by Trefoil factor-3 (TFF-3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV clearance</measure>
    <time_frame>1 year</time_frame>
    <description>measured by HCV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver fibrosis</measure>
    <time_frame>1 year</time_frame>
    <description>liver stiffness measured by transient elastography</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir / Grazoprevir Oral Tablet [Zepatier]</intervention_name>
    <description>HCV treatment</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma and PBMC (peripheral blood mononuclear cell)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        25 Genotype 1 or 4 HCV-infected women from the San Francisco WIHS site and 25 Genotype 1 or
        4 HCV-infected men from the San Francisco VA Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Active Genotype 1 or 4 HCV infection (If with Genotype 1a infection, only those without
        baseline NS5A resistance mutation will be included; Genotype 4 HCV infection is uncommon in
        both study populations). Subjects with HIV coinfection are included. We will not exclude
        patients who have severe Chronic Kidney Disease, are on dialysis, or have undergone kidney
        transplant.

        Exclusion Criteria:

          1. HCV genotype 2, 3, 5, or 6 infection

          2. Previous virologic failure to regimens containing an NS5A inhibitor

          3. Decompensated liver disease (Child-Pugh Class B or C)

          4. Albumin below 3g/dL

          5. Platelet count below 75,000

          6. Any condition that the investigator considers a contraindication to study
             participation including limited life expectancy

          7. Pregnant or breastfeeding woman

          8. Hepatitis B virus (HBV) surface antigen positive (Note: Patients positive for the HBV
             core antibody will not be excluded, but will have HBV DNA levels checked and will be
             monitored while on Direct Acting Antivirals (DAA) therapy and medically managed as
             considered appropriate)

          9. Documented ongoing nonadherence to prescribed medications or medical treatment,
             failure to complete HCV disease evaluation appointments and procedures or unable to
             commit to scheduled followup/monitoring for the duration of treatment

         10. Poor venous access not allowing screening laboratory collection

         11. Known hypersensitivity to elbasvir/grazoprevir

         12. Co-administration with drugs that are 1) strong CYP3A inducers (e.g., phenytoin,
             carbamazepine, rifampin); 2) OATP1B1/3 inhibitors (e.g., cyclosporine, darunavir,
             atazanavir, tipranavir, lopinavir or saquinavir) or 3) efavirenz
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis C Tien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phyllis C Tien, MD</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>22577</phone_ext>
    <email>phyllis.tien@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather S Freasier, MS</last_name>
    <phone>415-379-5518</phone>
    <email>heather.freasier@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phyllis C Tien, MD</last_name>
      <phone>415-221-4810</phone>
      <phone_ext>22577</phone_ext>
      <email>phyllis.tien@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Freasier, MS</last_name>
      <phone>415-379-5518</phone>
      <email>heather.freasier@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Francisco Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Phyllis Tien</investigator_full_name>
    <investigator_title>Professor of Medicine and Clinical Pharmacy and Staff Physician</investigator_title>
  </responsible_party>
  <keyword>genotype 1</keyword>
  <keyword>genotype 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Elbasvir-grazoprevir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

